Sepsis Emerging Therapies, Key Players, Therapeutic Assessment Pipeline Report 2022

DelveInsight's, "Sepsis Pipeline Insight, 2022," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Sepsis: An Overview

Sepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection. Sepsis is sometimes called septicaemia or blood poisoning. If not recognized early, it can lead to septic shock, multiple organ failure and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries where it represents a major cause of maternal and neonatal morbidity and mortality. Implementing preventive measures against infections, such as good hygiene practices, ensuring access to vaccination programs, improved sanitation and water quality and availability, and other infection prevention and control best practices both in the community and health care settings, are key steps in reducing the occurrence of sepsis.

Request for sample and discover more about the report offerings- https://www.delveinsight.com/sample-request/sepsis-pipeline-insight?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Regions Covered in the report
• Global

Sepsis Pipeline Report

The Sepsis pipeline report lays down detailed profiles of the pipeline assets, a comparative analysis of clinical and non-clinical stage Sepsis products, inactive and dormant assets, and a comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Sepsis pipeline landscape.

Sepsis Treatment

Sepsis is a medical emergency. It needs to be treated as such. Sepsis should be treated as quickly and efficiently as possible as soon as it has been identified. Treatment includes rapid administration of antibiotics and fluids. The risk of death from sepsis increases by an average of up to 7.6% with every hour that passes before treatment begins.

Sepsis Pipeline Insights

Sepsis Pipeline Insight, 2022 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines. The assessment part of the report embraces, in depth Sepsis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sepsis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Understand more about the Sepsis disease- https://www.delveinsight.com/report-store/sepsis-pipeline-insight?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Sepsis Phases
DelveInsight's report covers around 40+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Sepsis Emerging Drugs

Rezafungin: Cidara Therapeutics
Rezafungin is a novel, once-weekly antifungal being developed for the treatment and prevention of serious fungal infections. Rezafungin (formerly CD101) is an echinocandin drug, currently in Phase III clinical development for candidemia, invasive candidiasis and for prophylaxis of invasive fungal infections due to Candida, Aspergillus, and Pneumocystis. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and fast track designations for rezafungin.

VBI-S: Vivacelle Bio
VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the body's fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. The therapy is currently under phase II clinical evaluation for the treatment of hypovolemia due to sepsis/septic shock.

Sepsis Pipeline Companies include-
• Cidara Therapeutics
• Vivacelle Bio
• SciClone Pharmaceuticals
• Asahi Kasei Pharma
• Sanofi
• Shionogi
• Revimmune
• Inotrem
• Enlivex Therapeutics
• Abionyx, and Several Others

Sepsis Pipeline Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Learn more about the emerging therapies- https://www.delveinsight.com/report-store/sepsis-pipeline-insight?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Sepsis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sepsis - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Sepsis Collaboration Deals
9. Late Stage Products (Phase III)
10. Rezafungin: Cidara Therapeutics
11. Mid Stage Products (Phase II)
12. VBI-S: Vivacelle Bio
13. Early Stage Products (Phase I)
14. HY209: Shaperon
15. Early Stage Products (Preclinical)
16. Selinexor: Karyopharm Therapeutics
17. Inactive Products
18. Sepsis Key Companies
19. Sepsis Key Products
20. Sepsis- Unmet Needs
21. Sepsis- Market Drivers and Barriers
22. Sepsis- Future Perspectives and Conclusion
23. Sepsis Analyst Views
24. Sepsis Key Companies
25. Appendix

Do you have any query related to the report? If yes, click here- https://www.delveinsight.com/report-store/sepsis-pipeline-insight?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.